The dilution-and-runway math, plainly. In its quarterly report for the period ended September 30, 2020, filed October 30, 2020, Moderna reported nine-month revenue of about $232 million against nine-month research and development expense of roughly $611 million. The gap is the whole story: this is a company spending well ahead of what its products bring in.
That is normal for a platform biotech racing multiple candidates through the clinic at once, but it has a financing consequence. When operating spend outruns revenue by that margin, the balance sheet — cash raised from the markets — is what keeps the lights on and the trials running. The runway is bought, not earned.
The investor-protective question is therefore not “how fast is revenue growing” but “how long does the cash last at this burn, and what does it cost shareholders to refill it.” At this stage of 2020, Moderna’s answer rests on its accumulated cash position and its continued access to public-market financing, not on a marketed product.
Read forward from this filing, the company is a bet on conversion: turning an expensive, financed development engine into approved products that eventually self-fund. As of the third quarter of 2020, that conversion has not happened yet — the 10-Q describes the effort, not the payoff.
Every figure above is drawn from the company's primary SEC filing — surfaced through EdgarBeast, the SEC filing data API and evidence index — and verifiable against the filing on sec.gov.